X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AJANTA PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AJANTA PHARMA ASTRAZENECA PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 142.1 19.5 729.8% View Chart
P/BV x 21.6 4.5 482.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
AJANTA PHARMA
Mar-18
ASTRAZENECA PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2851,818 70.7%   
Low Rs6341,106 57.3%   
Sales per share (Unadj.) Rs189.6239.5 79.2%  
Earnings per share (Unadj.) Rs-0.252.8 -0.4%  
Cash flow per share (Unadj.) Rs3.859.5 6.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6230.0 29.8%  
Shares outstanding (eoy) m25.0088.77 28.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.16.1 82.9%   
Avg P/E ratio x-4,712.727.7 -17,017.4%  
P/CF ratio (eoy) x249.624.6 1,015.8%  
Price / Book Value ratio x14.06.4 219.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,988129,782 18.5%   
No. of employees `0001.66.8 22.9%   
Total wages/salary Rs m1,6053,765 42.6%   
Avg. sales/employee Rs Th3,040.23,128.4 97.2%   
Avg. wages/employee Rs Th1,029.2554.0 185.8%   
Avg. net profit/employee Rs Th-3.3689.7 -0.5%   
INCOME DATA
Net Sales Rs m4,74021,258 22.3%  
Other income Rs m92242 38.1%   
Total revenues Rs m4,83221,499 22.5%   
Gross profit Rs m-1306,584 -2.0%  
Depreciation Rs m101596 17.0%   
Interest Rs m04 0.0%   
Profit before tax Rs m-1396,226 -2.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,539 0.3%   
Profit after tax Rs m-54,686 -0.1%  
Gross profit margin %-2.731.0 -8.8%  
Effective tax rate %-3.724.7 -14.8%   
Net profit margin %-0.122.0 -0.5%  
BALANCE SHEET DATA
Current assets Rs m2,72612,236 22.3%   
Current liabilities Rs m2,4353,461 70.4%   
Net working cap to sales %6.141.3 14.9%  
Current ratio x1.13.5 31.7%  
Inventory Days Days7460 122.5%  
Debtors Days Days4184 48.2%  
Net fixed assets Rs m1,03511,140 9.3%   
Share capital Rs m50177 28.3%   
"Free" reserves Rs m94220,237 4.7%   
Net worth Rs m1,71620,414 8.4%   
Long term debt Rs m010 0.0%   
Total assets Rs m4,15624,486 17.0%  
Interest coverage xNM1,519.4-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.9 131.4%   
Return on assets %-0.119.2 -0.6%  
Return on equity %-0.323.0 -1.3%  
Return on capital %030.5 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37511,667 3.2%   
Fx outflow Rs m4701,616 29.1%   
Net fx Rs m-9610,052 -1.0%   
CASH FLOW
From Operations Rs m-82,854 -0.3%  
From Investments Rs m-146-2,604 5.6%  
From Financial Activity Rs m862-2 -43,110.0%  
Net Cashflow Rs m709248 285.6%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 1.6 19.4%  
FIIs % 15.7 7.6 206.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.0 53.5%  
Shareholders   12,856 20,968 61.3%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Idea Cellular Plunges 6%(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading marginally below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 25, 2018 03:17 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS